The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
A genetic testing utilization service launched by Stanford in 2015 helped cut the number of inappropriately ordered tests in half and saved about $250,000 during the first year.
Clinicians in the hospital will use IBM's Watson to identify possible options for diagnosing and treating rare pediatric diseases starting with kidney disease.
Most study participants seem to be increasingly comfortable contributing their genetic results to their electronic medical records as the study progresses.
Use of the blood culture panel in a community hospital setting led to shorter time to targeted treatment for the patient and a shorter stay in the hospital.
The collaboration will explore the clinical utility of Trovagene's platform for detecting and monitoring EGFR mutations in lung cancer patients.
Originally published Oct. 12.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.